Functional connectivity of the subcallosal cingulate cortex and differential outcomes to treatment with cognitive-behavioral therapy or antidepressant medication for major depressive disorder

American Journal of Psychiatry

Volumn 174, Issue 6, 2017, Pages 533-545

  Dunlop, Boadie W ^a,b,c,d,e   Rajendra, Justin K ^a,b,c,d,e   Craighead, W Edward ^a,b,c,d,e   Kelley, Mary E ^a,b,c,d,e   McGrath, Callie L ^a,b,c,d,e   Choi, Ki Sueng ^a,b,c,d,e   Kinkead, Becky ^a,b,c,d,e   Nemeroff, Charles B ^a,b,c,d,e   Mayberg, Helen S ^a,b,c,d,e  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE; ESCITALOPRAM; CITALOPRAM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CINGULATE GYRUS; COGNITIVE BEHAVIORAL THERAPY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG TREATMENT FAILURE; FEMALE; FUNCTIONAL CONNECTIVITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HAMILTON DEPRESSION RATING SCALE; HUMAN; IMAGE ANALYSIS; INSULA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MESENCEPHALON; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REMISSION; RESTING STATE NETWORK; SENSITIVITY AND SPECIFICITY; SUBCALLOSAL GYRUS; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VENTROLATERAL PREFRONTAL CORTEX; VENTROMEDIAL PREFRONTAL CORTEX; ADOLESCENT; COGNITIVE THERAPY; COMPARATIVE STUDY; COMPUTER ASSISTED DIAGNOSIS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC IMAGING; DRUG EFFECTS; HEMISPHERIC DOMINANCE; MIDDLE AGED; NERVE CELL NETWORK; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; PREFRONTAL CORTEX; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; COGNITIVE THERAPY; DEPRESSIVE DISORDER, MAJOR; DOMINANCE, CEREBRAL; DULOXETINE HYDROCHLORIDE; FEMALE; GYRUS CINGULI; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NERVE NET; OUTCOME ASSESSMENT (HEALTH CARE); PREFRONTAL CORTEX; PSYCHIATRIC STATUS RATING SCALES; YOUNG ADULT;

EID: 85020117913     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2016.16050518     Document Type: Article

References (86)

1. Hasler G, Drevets WC, Manji HK, et al: Discovering endophenotypes for major depression. Neuropsychopharmacology 2004; 29: 1765-1781
2. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 3rd ed. Washington, DC, American Psychiatric Association, 2010
3. Craighead WE, Dunlop BW: Combination psychotherapy and antidepressant medication treatment for depression: for whom, when, and how. Annu Rev Psychol 2014; 65:267-300
4. Schatzberg AF, Rush AJ, Arnow BA, et al: Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. Arch Gen Psychiatry 2005; 62:513-520
5. Dunlop BW: Evidence-based applications of combination psychotherapy and pharmacotherapy for depression. Focus 2016; 14: 156-173
6. Collins FS, Varmus H: A new initiative on precision medicine. N Engl J Med 2015; 372:793-795
7. Weitz E, Hollon SD, Twisk J, et al: Does baseline depression severity moderate outcomes between CBT and pharmacotherapy? An individual participant data meta-Analysis. JAMA Psychiatry 2015; 72: 1102-1109
8. Cuijpers P, Weitz E, Lamers F, et al: Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression. Depress Anxiety (Epub ahead of print, Dec 6, 2016)
9. Paulus MP: Pragmatism instead of mechanism. JAMA Psychiatry 2015; 72:631-632
10. Dunlop BW, Kelley ME, Aponte-Rivera V, et al: Effects of patient preferences on outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study. Am J Psychiatry 2017; 174:546-556
11. Dunlop BW: Prediction of treatment outcomes in major depressive disorder. Expert Rev Clin Pharmacol 2015; 8:669-672
12. Ressler KJ, Mayberg HS: Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 2007; 10:1116-1124
13. Williams LM: Precision psychiatry: a neural circuit taxonomy for depression and anxiety. Lancet Psychiatry 2016; 3:472-480
14. Goldapple K, Segal Z, Garson C, et al: Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 2004; 61:34-41
15. Fu CH, Steiner H, Costafreda SG: Predictive neural biomarkers of clinical response in depression: a meta-Analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol Dis 2013; 52:75-83
16. Chi KF, Korgaonkar M, Grieve SM: Imaging predictors of remission to anti-depressant medications in major depressive disorder. J Affect Disord 2015; 186:134-144
17. Siegle GJ, Thompson WK, Collier A, et al: Toward clinically useful neuroimaging in depression treatment: prognostic utility of subgenual cingulate activity for determining depression outcome in cognitive therapy across studies, scanners, and patient characteristics. Arch Gen Psychiatry 2012; 69:913-924
18. Ritchey M, Dolcos F, Eddington KM, et al: Neural correlates of emotional processing in depression: changes with cognitive behavioral therapy and predictors of treatment response. J Psychiatr Res 2011; 45:577-587
19. Fu CH, Williams SC, Cleare AJ, et al: Neural responses to sad facial expressions in major depression following cognitive behavioral therapy. Biol Psychiatry 2008; 64:505-512
20. Dichter GS, Gibbs D, Smoski MJ: A systematic review of relations between resting-state functional-MRI and treatment response in major depressive disorder. J Affect Disord 2015; 172:8-17
21. Milak MS, Parsey RV, Lee L, et al: Pretreatment regional brain glucose uptake in the midbrain onPETmaypredict remission from a major depressive episode after three months of treatment. Psychiatry Res 2009; 173:63-70
22. WilliamsLM,Korgaonkar MS,Song YC, et al:Amygdala reactivity to emotional faces in the prediction of general and medication-specific responses to antidepressant treatment in the randomized iSPOT-D trial. Neuropsychopharmacology 2015; 40:2398-2408
23. Samson AC, Meisenzahl E, Scheuerecker J, et al: Brain activation predicts treatment improvement in patients with major depressive disorder. J Psychiatr Res 2011; 45:1214-1222
24. Rush AJ: Narrowing the gaps between what we know and what we do in psychiatry. J Clin Psychiatry 2015; 76:1366-1372
25. Dunlop BW, Mayberg HS: Neuroimaging-based biomarkers for treatment selection in major depressive disorder. Dialogues Clin Neurosci 2014; 16:479-490
26. McGrath CL, Kelley ME, Holtzheimer PE, et al: Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 2013; 70:821-829
27. Dunlop BW, Kelley ME, McGrath CL, et al: Preliminary findings supporting insula metabolic activity as a predictor of outcome to psychotherapy and medication treatments for depression. J Neuropsychiatry Clin Neurosci 2015; 27:237-239
28. Wang L, Hermens DF, Hickie IB, et al: A systematic review of resting-state functional-MRI studies in major depression. J Affect Disord 2012; 142:6-12
29. Salerian AJ, Altar CA: The prefrontal cortex influence over subcortical and limbic regions governs antidepressant response by N=H/(M+R). Psychiatry Res 2012; 204:1-12
30. Mayberg HS, Liotti M, Brannan SK, et al: Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999; 156:675-682
31. Smith R, Fadok RA, Purcell M, et al: Localizing sadness activation withinthesubgenual cingulate in individuals: a novelfunctionalMRI paradigm for detecting individual differences in the neural circuitry underlying depression. Brain Imaging Behav 2011; 5:229-239
32. Greicius MD, Flores BH, Menon V, et al: Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol Psychiatry 2007; 62:429-437
33. Little JT, Ketter TA, Kimbrell TA, et al: Venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls. Psychopharmacol Bull 1996; 32:629-635
34. Brody AL, Saxena S, Silverman DH, et al: Brain metabolic changes in major depressive disorder from pre-to post-treatment with paroxetine. Psychiatry Res 1999; 91:127-139
35. Konarski JZ, KennedySH, Segal ZV, et al: Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. J Psychiatry Neurosci 2009; 34:175-180
36. McGrath CL, Kelley ME, Dunlop BW, et al: Pretreatment brain states identify likely nonresponse to standard treatments for depression. Biol Psychiatry 2014; 76:527-535
37. Mayberg HS, Lozano AM, Voon V, et al: Deep brain stimulation for treatment-resistant depression. Neuron 2005; 45:651-660
38. Riva-Posse P, Choi KS, Holtzheimer PE, et al:Defining critical white matter pathways mediating successful subcallosal cingulate deep brain stimulation for treatment-resistant depression. Biol Psychiatry 2014; 76:963-969
39. Dunlop BW, Binder EB, Cubells JF, et al: Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT): study protocol for a randomized controlled trial. Trials 2012; 13:106
40. First MB, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0). New York, Biometrics Research Department, New York State Psychiatric Institute, 1995
41. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
42. Beck AT, Rush AJ, ShawBF, et al: Cognitive Therapy of Depression. New York, Guilford, 1979
43. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50-55
44. Beck AT, Ward CH, Mendelson M, et al: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-571
45. Bernstein DP, Fink L: Childhood trauma questionnaire manual. San Antonio, Tex, Psychological Corporation; 1998
46. Heberlein KA, Hu X: Simultaneous acquisition of gradient-echo and asymmetric spin-echo for single-shot z-shim: Z-SAGA. Magn Reson Med 2004; 51:212-216
47. Power JD, Barnes KA, Snyder AZ, et al: Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage 2012; 59:2142-2154
48. Cox RW, Hyde JS: Software tools for analysis and visualization of fMRI data. NMR Biomed 1997; 10:171-178
49. Desikan RS, Ségonne F, Fischl B, et al: An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006; 31:968-980
50. Gutman DA, Holtzheimer PE, Behrens TE, et al: A tractography analysis of two deep brain stimulation white matter targets for depression. Biol Psychiatry 2009; 65:276-282
51. Taylor PA, Saad ZS: FATCAT: (an efficient) Functional and Tractographic Connectivity Analysis Toolbox. Brain Connect 2013; 3:523-535
52. Owens MJ, DunlopBW,Plott S, et al: Poster presentation: Estimates of serotonin or norepinephrine transporter occupancy do not predict efficacy in a 12 week trial. Presented at the proceedings of the 54th Annual Meeting of the American College of Neuropsychopharmacology, Hollywood, Fla, 2015
53. Chen G, Adleman NE, Saad ZS, et al: Applications of multivariate modeling to neuroimaging group analysis: a comprehensive alternative to univariate general linear model. Neuroimage 2014; 99: 571-588
54. Cohen J: Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ, Lawrence Erlbaum Associated, 1988
55. Youden WJ: Index for rating diagnostic tests. Cancer 1950; 3:32-35
56. Ritchey M, Dolcos F, Eddington KM, et al: Neural correlates of emotional processing in depression: changes with cognitive behavioral therapy and predictors of treatment response. J Psychiatr Res 2011; 45:577-587
57. Fu CH, Williams SC, Cleare AJ, et al: Neural responses to sad facial expressions in major depression following cognitive behavioral therapy. Biol Psychiatry 2008; 64:505-512
58. Wager TD, Davidson ML, Hughes BL, et al: Prefrontal-subcortical pathways mediating successful emotion regulation. Neuron 2008; 59:1037-1050
59. Ochsner KN, Gross JJ: Cognitive emotion regulation: insights from social cognitive and affective neuroscience. Curr Dir Psychol Sci 2008; 17:153-158
60. D'Esposito M, Postle BR, Rypma B: Prefrontal cortical contributions toworking memory: evidence from event-related fMRI studies. Exp Brain Res 2000; 133:3-11
61. Disner SG, Beevers CG, Haigh EA, et al: Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci 2011; 12:467-477
62. Rive MM, van Rooijen G, Veltman DJ, et al: Neural correlates of dysfunctional emotion regulation in major depressive disorder: a systematic review of neuroimaging studies. Neurosci Biobehav Rev 2013; 37:2529-2553
63. LiottiM,MaybergHS,McGinnisS, et al:Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression.AmJ Psychiatry 2002; 159:1830-1840
64. Connolly CG, Wu J, Ho TC, et al: Resting-state functional connectivity of subgenual anterior cingulate cortex in depressed adolescents. Biol Psychiatry 2013; 74:898-907
65. Qiao L, Wei DT, Li WF, et al: Rumination mediates the relationship between structural variations in ventrolateral prefrontal cortex and sensitivity to negative life events. Neuroscience 2013; 255:255-264
66. Zaki J, Davis JI, Ochsner KN: Overlapping activity in anterior insula during interoception and emotional experience. Neuroimage 2012; 62:493-499
67. zu Eulenburg P, Baumgärtner U, Treede RD, et al: Interoceptive and multimodal functions of the operculo-insular cortex: tactile, nociceptive and vestibular representations. Neuroimage 2013; 83:75-86
68. Mayer EA: Gut feelings: the emerging biology of gut-brain communication. Nat Rev Neurosci 2011; 12:453-466
69. Milak MS, Parsey RV, Lee L, et al: Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after threemonths of treatment. Psychiatry Res 2009; 173:63-70
70. An X, Bandler R, Ongür D, et al: Prefrontal cortical projections to longitudinal columns in the midbrain periaqueductal gray in macaque monkeys. J Comp Neurol 1998; 401:455-479
71. CannonDM,Ichise M,Rollis D, et al: Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry 2007; 62:870-877
72. Bingel U, Lorenz J, Schoell E, et al: Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain 2006; 120:8-15
73. Warden MR, Selimbeyoglu A, Mirzabekov JJ, et al: A prefrontal cortex-brainstem neuronal projection that controls response to behavioural challenge. Nature 2012; 492:428-432
74. Amat J, Paul E, Zarza C, et al: Previous experience with behavioral control over stress blocks the behavioral and dorsal raphe nucleus activating effects of later uncontrollable stress: role of the ventral medial prefrontal cortex. J Neurosci 2006; 26:13264-13272
75. Veerakumar A, Challis C, Gupta P, et al: Antidepressant-like effects of cortical deep brain stimulation coincide with proneuroplastic adaptations of serotonin systems. Biol Psychiatry 2014; 76:203-212
76. Piñeyro G, Blier P: Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 1999; 51:533-591
77. Mayberg HS: Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003; 65: 193-207
78. Drevets WC, Price JL, Furey ML: Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 2008; 213:93-118
79. Bludau S, Bzdok D, Gruber O, et al: Medial prefrontal aberrations in major depressive disorder revealed by cytoarchitectonically informed voxel-based morphometry. Am J Psychiatry 2016; 173: 291-298
80. Fox MD, Snyder AZ, Vincent JL, et al: The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci USA 2005; 102:9673-9678
81. Carmichael ST, Price JL: Connectional networks within the orbital and medial prefrontal cortex of macaque monkeys. J Comp Neurol 1996; 371:179-207
82. Ongür D, Price JL: The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans. Cereb Cortex 2000; 10:206-219
83. Von Der Heide RJ, Skipper LM, Klobusicky E, et al: Dissecting the uncinate fasciculus: disorders, controversies and a hypothesis. Brain 2013; 136:1692-1707
84. Fox AS, Oler JA, Shackman AJ, et al: Intergenerational neural mediators of early-life anxious temperament. Proc Natl Acad Sci USA 2015; 112:9118-9122
85. Delaveau P, Jabourian M, Lemogne C, et al: Brain effects of antidepressants in major depression: a meta-Analysis of emotional processing studies. J Affect Disord 2011; 130:66-74
86. Anand A, Li Y, Wang Y, et al: Reciprocal effects of antidepressant treatment on activity and connectivity of the mood regulating circuit: an FMRI study. J Neuropsychiatry Clin Neurosci 2007; 19: 274-282